NEWS
Shengnuo Bio Enters Strategic Cooperation with Brazilian "Belt and Road" Institution to Forge New Pathway for Peptide APIs in South America
Shengnuo Bio has signed a strategic agreement with a Brazilian "Belt and Road" institution to cooperate on the supply of peptide APIs, technology exchange, and market channel development, with a focus on promoting GLP-1 class APIs such as Semaglutide and Tirzepatide in the Brazilian market. This collaboration marks the extension of the company's overseas presence into the core South American market and provides a practical pathway for China-Brazil biomedical cooperation under the "Belt and Road" framework.
Shengnuo Bio recently formally signed a strategic cooperation framework agreement with the Brazilian "Belt and Road" Culture and Economic Development Fund Association. This collaboration will focus on three core areas: the supply of peptide active pharmaceutical ingredients (APIs), exchange of pharmaceutical technologies, and the establishment of market channels. It marks the extension of Shengnuo Bio's overseas strategic layout into the core South American market, solidifying its position as a leading enterprise in China's peptide API sector.
Leveraging its full industrial chain advantages in the R&D and large-scale production of peptide APIs, Shengnuo Bio will prioritize promoting the alignment of GLP-1 class APIs, including Semaglutide and Tirzepatide, along with related pharmaceutical technologies, with the Brazilian market. The cooperating party, serving as a significant platform in Brazil for promoting international industrial cooperation and economic exchanges, possesses notable advantages in integrating local market resources and facilitating policy coordination. This will provide strong support for the entry of Shengnuo Bio's API products and technologies into the South American market.
Mr. Carlos Eduardo Fioravanti da Costa, President of the Brazilian "Belt and Road" Culture and Economic Development Fund Association, stated that the Brazilian pharmaceutical market holds vast development potential. Shengnuo Bio's profound technological expertise and well-established product portfolio in the peptide API field highly align with Brazil's needs to enhance its local pharmaceutical and healthcare industry capabilities. The Association will actively leverage its role in resource integration and platform collaboration to promote the practical implementation of the cooperation between the two parties.
Currently, China and Brazil continue to deepen cooperation across various fields under the "Belt and Road" framework, with biomedicine emerging as a key focus of mutual interest. This strategic cooperation between Shengnuo Bio and the specialized Brazilian institution not only aids the company in expanding its global business layout but also provides a referential practical model for Chinese pharmaceutical enterprises seeking to explore emerging markets through international collaboration.
Chengdu Shengnuo Biopharm Co., Ltd.
December 8, 2025
Hot news
Shengnuo Bio has signed a strategic agreement with a Brazilian "Belt and Road" institution to cooperate on the supply of peptide APIs, technology exchange, and market channel development, with a focus on promoting GLP-1 class APIs such as Semaglutide and Tirzepatide in the Brazilian market. This collaboration marks the extension of the company's overseas presence into the core South American market and provides a practical pathway for China-Brazil biomedical cooperation under the "Belt and Road" framework.
2025-12-08
The 93rd API China kicked off successfully in Chongqing on November 12, with Shengnuo Biopharm (Booth N5 Hall 5L25) getting off to a strong start on the first day. The exhibition floor was buzzing with professional exchanges, as the company's demonstration of its integrated, end-to-end capabilities in peptide APIs and CDMO services attracted numerous industry professionals for in-depth discussions and garnered widespread recognition. The exhibition is still ongoing, and we sincerely invite colleagues from across the industry to visit our booth to continue the dialogue and explore collaborative opportunities.
2025-11-12
Chengdu Shengnuo Biopharm sincerely invites you to attend the 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China 2025). Join us from November 12–14, 2025, at Booth No. 5L25, Hall N5, Chongqing International Expo Center, as we explore cutting-edge technologies and collaboration opportunities in the peptide sector.
2025-11-11
October 30, 2025 – Chengdu Shengnuo Biopharm Co., Ltd. held the project commencement ceremony in Dayi Economic Development Zone, marking the official start of construction for the Semaglutide, Tirzepatide, and other peptide Active Pharmaceutical Ingredient (API) industrialization base project.
2025-10-31